

191. Synthesis of Urinary Metabolites of Retinoic Acid

by **Tong Hei Kim, Kenji Kon, and Sachihiko Isoe***


Institute of Organic Chemistry, Faculty of Science, Osaka City University, Sugimoto, Sumiyoshi-ku, Osaka 558, Japan

(21.III.83)

Summary

Urinary metabolites 5-methyl-5-[2-(2,6,6-trimethyl-3-oxo-1-cyclohexen-1-yl)-vinyl]-2-tetrahydrofuranone (**1**) and 5-[2-(6-hydroxymethyl-2,6-dimethyl-3-oxo-1-cyclohexen-1-yl)vinyl]-5-methyl-2-tetrahydrofuranone (**2**) of retinoic acid have been synthesized from 4-[2,2,6-trimethyl-3-(tetrahydro-2*H*-pyran-2-yl)oxy-1-cyclohexen-1-yl]-3-buten-2-one (**4**) and methyl 2-(3,3-ethylenedioxy-1-butenyl)-1,3-dimethyl-4-oxo-2-cyclohexene-1-carboxylate (**5**).

Retinoic acid possesses vitamin-A-like activity [1] and has been applied in acne therapy. Three urinary metabolites 5-methyl-5-[2-(2,6,6-trimethyl-3-oxo-1-cyclohexen-1-yl)vinyl]-2-tetrahydrofuranone (**1**), 5-[2-(6-hydroxymethyl-2,6-dimethyl-3-oxo-1-cyclohexen-1-yl)vinyl]-5-methyl-2-tetrahydrofuranone (**2**) and 6-(6-hydroxymethyl-2,6-dimethyl-3-oxo-1-cyclohexen-1-yl)-4-methyl-4-hexenoic acid (**3**) have been isolated in microgram amounts after the intraperitoneal administration of retinoic acid to rats [2]. Although metabolites of retinoic acid possesses biological activity [3], nothing is known about the biological activity of these three urinary metabolites.




As an extension of our synthetic study of biologically active metabolites of carotenoids [4] [5], we are interested in the synthesis of the metabolites of retinoic acid. We now describe the first synthesis of metabolites **1** and **2**.


For the synthesis of **1** starting material 4-[2,2,6-trimethyl-3-(tetrahydro-2 *H*-pyran-2-yl)oxy-1-cyclohexen-1-yl]-3-buten-2-one (**4**) was transformed into 1-[2,6,6-trimethyl-3-(tetrahydro-2 *H*-pyran-2-yl)oxy-1-cyclohexen-1-yl]-3,4-epoxy-3-methyl-1-butene (**6**) in high yield by raising the temperature to 110–120° after treatment with dimethylsulfonium methylide at –15°. Treatment of **6** with diethyl malonate (NaOEt, EtOH) gave ethyl 5-methyl-5-[2-[2,6,6-trimethyl-3-(tetrahydro-2 *H*-pyran-2-yl)oxy-1-cyclohexen-1-yl]vinyl]-2-oxotetrahydrofuran-3-carboxylate (**7**) (72% from **4**). Deprotection (TsOH, aq. THF) of **7** followed by oxidation (CrO₃/pyridine complex) yielded ethyl 5-methyl-5-[2-(2,6,6-trimethyl-3-oxo-1-cyclohexen-1-yl)-vinyl]-2-oxotetrahydrofuran-3-carboxylate (**8**) (75% from **7**) which was hydrolyzed (KOH, aq. EtOH), and decarboxylated to afford **1** (51% from **8**). Metabolite **1** was also prepared from **4** [6] by reaction with 3,3-ethylenedioxypropylmagnesium bromide (**9**) affording 3-methyl-1-[2,6,6-trimethyl-3-(tetrahydro-2 *H*-pyran-2-yl)oxy-1-cyclohexen-1-yl]-6,6-ethylenedioxy-1-hexen-3-ol (**10**) (77%), which was deprotected (TsOH, aq. THF) and oxidized (CrO₃/pyridine complex) to give **1** (45% from **10**).

Next, synthesis of **2** was achieved by the *Grignard* reaction. Methyl 2-(3,3-ethylenedioxy-1-butenyl)-1,3-dimethyl-4-oxo-2-cyclohexene-1-carboxylate (**5**) was selected as starting material, which was the intermediate in our early synthesis of trisporic acids [5]. Conversion of **5** into 4-(acetoxymethyl)-2,4-dimethyl-3-(3-oxo-1-butenyl)-2-cyclohexen-1-yl acetate (**11**) was carried out as usual (*i.* LAH, ether; *ii.* Ac₂O, pyridine; *iii.* 50% AcOH; 87.5% from **5**). *Grignard* reaction of **11** with **9** (THF, 5°, 20 h) afforded 4-(acetoxymethyl)-3-(6,6-ethylenedioxy-3-hydroxy-3-methyl-1-hexenyl)-2,4-dimethyl-2-cyclohexen-1-yl acetate (**12**) and [2-(6,6-ethylenedioxy-3-hydroxy-3-methyl-1-hexenyl)-4-hydroxy-1,3-dimethyl-2-cyclohexen-1-yl]-methyl acetate (**13**) (69.1%) in a ratio of 4:1. Treatment of **12** with TsOH in aq. THF yielded the corresponding hemiacetal, which, without purification, was oxidized by *Collins* reagent to give {2-[2-(2-methyl-5-oxo-2-tetrahydrofuryl)vinyl]-1,3-dimethyl-4-oxo-2-cyclohexene-1-yl}methyl acetate (**14**) (47%) together with 4-(acetoxymethyl)-3-[2-(2-methyl-5-oxo-2-tetrahydrofuryl)vinyl]-2,4-dimethyl-2-cyclohexene-1-yl acetate (**15**) (21.5%). Finally hydrolysis of **14** (K₂CO₃, aq. MeOH) followed by lactonization (TsOH, THF, r.t., 20 h) gave **2** (65% from **14**).

Scheme 1



The ¹H-NMR and IR spectra and MS fragmentation of the synthetic metabolites **1** and **2** are consistent with those of the biological metabolites **1** and **2**.



REFERENCES

- [1] J. E. Dowling & G. Wald, Proc. Natl. Acad. Sci. U.S.A. 46, 587 (1960).
- [2] R. Hänni, F. Bigler, W. Meister & G. Englert, Helv. Chim. Acta 59, 2221 (1976).
- [3] K. Yagishita, P. R. Sundaresan & G. Wolf, Fed. Proc., Fed. Am. Soc. Exp. Biol. 23, 294 (1964); K. Yagishita, P. R. Sundaresan & G. Wolf, Nature 203, 410 (1964).
- [4] S. Isoe, S. Katsumura & T. Sakan, Helv. Chim. Acta 56, 1514 (1973); S. Isoe, S. B. Hyeon, S. Katsumura & T. Sakan, Tetrahedron Lett. 1972, 2517; S. Isoe, S. Katsumura, S. B. Hyeon & T. Sakan, ibid. 1971, 1089.
- [5] S. Isoe, Y. Hayase & T. Sakan, Tetrahedron Lett. 1971, 3691.
- [6] R. Hänni, F. Bigler, W. Vetter, G. Englert & P. Loeliger, Helv. Chim. Acta 60, 2309 (1977).